Human Anti-MERS-CoV RBD Recombinant Antibody (MRO-895LC)

Customer Review

There are currently no Customer reviews or questions for MRO-895LC. Click the button above to contact us or submit your feedback about this product.

Citations

1. Folegatti, Pedro M., et al. "Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial." The Lancet Infectious Diseases 20.7 (2020): 816-826. https://doi.org/10.1016/S1473-3099(20)30160-2
   This study reports a phase 1 clinical trial evaluating the safety and immunogenicity of ChAdOx1 MERS, a candidate vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV). In this dose-escalation, open-label trial involving 24 healthy adults, participants received a single intramuscular injection of the simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein at three different doses. The vaccine proved safe and well-tolerated at all doses, with primarily mild adverse events. A single dose induced significant T-cell responses in all participants and antibody responses in 92% of participants, with responses persisting for at least one year after vaccination. Neutralizing antibodies against live MERS-CoV were observed in 44% of participants in the high-dose group.
   Creative Biolabs provided a recombinant human monoclonal antibody directed against the receptor binding domain (RBD) of MERS-CoV S1 (CAT#: MRO-895LC) that served as a neutralization control in the virus neutralizing assay. This antibody was critical for validating the methodology of the virus neutralization assay, providing a reference standard for full neutralization at a dilution of 1/512 (corresponding to 0.2 μg/mL), thus enabling reliable assessment of the vaccine's ability to induce functionally relevant antibody responses against MERS-CoV.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "MERS-CoV RBD"

Select a product category from the dropdown menu below to view related products.